Caesarean section · women with ruptured membranes in the third trimester for induction of labour.
Oral misoprostol showed no clear difference in caesarean section compared with placebo/no treatment (low certainty).
1 finding from 1 review
Uterine hyperstimulation with fetal heart rate changes · women with ruptured membranes in the third trimester for induction of labour.
It is very uncertain whether oral misoprostol changes uterine hyperstimulation with fetal heart rate changes compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Oxytocin augmentation · women with ruptured membranes in the third trimester for induction of labour.
Oral misoprostol probably leads to lower oxytocin augmentation compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
Uterine hyperstimulation without fetal heart rate changes · women with ruptured membranes in the third trimester for induction of labour.
It is very uncertain whether oral misoprostol changes uterine hyperstimulation without fetal heart rate changes compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Apgar score less than 7 at 5 minutes · women with ruptured membranes in the third trimester for induction of labour.
It is very uncertain whether oral misoprostol changes apgar score less than 7 at 5 minutes compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Admission to neonatal intensive care unit · women with ruptured membranes in the third trimester for induction of labour.
1 finding from 1 review
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
Resolution of symptoms · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all initial symptoms resolved (asymptomatic) at day 14 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Time to resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Quality of life at longest · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Adverse events during treatment period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Arrhythmias · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in worsening of clinical status: participants with clinical… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in improvement of clinical status: participants discharged alive at day… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Quality of life at longest · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
1 finding from 1 review
Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Adverse events during treatment period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in any adverse events during the study period compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Arrhythmias · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in cardiac arrhythmias during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review